Monday Jun 9
PharmAthene Granted U.S. Patent For Recombinant Bioscavenger
PharmAthene, Inc. announced today that the U.S. Patent and Trademark Office issued U.S. patent number 8,729,245 to PharmAthene, with claims that cover methods for the production of its recombinant butyrlcholinesterase bioscavenger in mammalian cells.
Monday Jun 9
PharmAthene, Inc. Granted U.S. Patent For Recombinant Bioscavenger
PharmAthene is initially developing rBChE as a pre- and post-exposure therapy for military and civilian victims of nerve agent attacks.
PharmAthene, Inc. Presents New SparVax?? Anthrax Vaccine Data At The...
In this study, three groups of twenty New Zealand White rabbits were vaccinated with SparVaxA via intramuscular injection, on study days 0 and 28 at doses of 3, 9, or 27 micrograms.
PharmAthene Presents New SparVaxA Anthrax Vaccine Data At The...
PharmAthene, Inc. announced today that new analytical data from the Company's SparVax anthrax vaccine program were presented at the 114 General Meeting of the American Society for Microbiology , held recently in Boston, Massachusetts.
Pharmathene, Inc Files (8-K) Disclosing Entry into a Material Definitive Agreement, Other Events
1 to the Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co., as sales agent , pursuant to which the Company may offer and sell, from time to time, through Cantor additional shares of common stock, par value .